Introduction {#s1}
============

Stress hyperglycemia is different from various forms of diabetes mellitus and is common after suffering an acute illness such as myocardial infarction or stroke, even in the absence of preexisting diabetes ([@B1]--[@B3]). Some studies ([@B3]), but not all ([@B4]), have demonstrated that stress hyperglycemia appeared to be a marker of increased risk of short-term mortality and poor functional outcome after ischemic stroke in non-diabetic patients. Therefore, the association between stress hyperglycemia and outcome of stroke was still controversial. Additionally, stress hyperglycemia was defined according to absolutely but not relatively increased fasting or random glucose in non-diabetic patients in most previous studies ([@B3], [@B4]).

Glycated hemoglobin (HbA1c) is a well-validated measure of mean glucose concentration over \~2--3 months, representing the mean level of blood glucose before the onset of acute ischemic stroke event ([@B5]). Thus, the ratio of acute fasting plasma glucose (FPG) to HbA1c means the relative hyperglycemia, namely stress hyperglycemia. Recent studies showed that relative hyperglycemia, defined as glucose-to-HbA1c ratio ([@B6]), or defined as admission glucose divided by estimated average glucose derived from HbA1c ([@B2], [@B7]), might be a better predicter of outcomes of critical illness than absolute hyperglycemia.

We aimed to explore the relationship between stress hyperglycemia, which was measured by glucose-to-HbA1c ratio, and the outcome of non-diabetic patients with acute ischemic stroke in a prospective stroke registry study in China.

Methods {#s2}
=======

Study Participants
------------------

We used data from the Abnormal Glucose Regulation in Patients with Acute Stroke across China (ACROSS-China) registry. ACROSS-China registry is a nationwide, prospective hospital-based registry study and the details on the rationale, study design and main results were published previously ([@B8]). The main objective of the ACROSS-China registry is to investigate the relationship between abnormal glucose regulation and the outcome of stroke patients within 14 days after the onset of stroke events from May 2008 to December 2009 in China. The protocol of the study was approved by the ethics committee of Beijing Tiantan Hospital and other participating centers. We obtained written informed consents from all patients or his/her representatives before enrollment. In this analysis, we only included those patients with acute ischemic stroke but without a history of diabetes.

Acute ischemic stroke was diagnosed by the World Health Organization criteria ([@B9]) and confirmed by brain computed tomography (CT) or magnetic resonance imaging (MRI). The severity of stroke was assessed by the National Institutes of Health Stroke Scale (NIHSS) on admission. We classified all ischemic stroke based on the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria ([@B10]) as large artery atherosclerosis, small artery occlusion, cardio embolism, other, and undetermined subtypes, respectively.

Data Collection
---------------

We collected baseline data on patient demographics, risk factors (blood pressure and smoking status), medical history (diabetes, hypertension, dyslipidemia, coronary heart disease, and atrial fibrillation), complications (pulmonary or urinary infection) and medication use during hospitalization for all patients. The data collections were performed through face-to-face interviews by trained research coordinators (all were neurologists) from participating centers and performed based on a standardized protocol. History of diabetes mellitus was defined as any self-reported history of diabetes mellitus and any use of anti-diabetic drugs before the symptom onset of stroke. All the historical and new observed atrial fibrillations were collected and further confirmed by at least one electrocardiogram.

Assessment of Stress Hyperglycemia
----------------------------------

The fasting venous blood samples within 2 days after hospitalization were drawn during the morning hours (range: 07:00--11:00) after an overnight fast (at least 8 h) to measure FPG and HbA1c. FPG was measured with an enzymatic method and HbA1c was tested using high-performance liquid chromatographic analysis ([@B11]). The laboratory personnel that performed the blood measurements were blinded to the patient\'s baseline characteristics and outcomes.

Stress hyperglycemia was estimated by the index of glucose-to-HbA1c ratio. We used the following formula to calculate glucose-to-HbA1c ratio: glucose-to-HbA1c ratio = FPG (mmol/L) / HbA1c (%). According to the quartiles of glucose-to-HbA1c ratio, the patients were further categorized into four even groups. Glucose-to-HbA1c ratio quantifies the extent of acute increase in blood glucose based on the baseline blood glucose levels.

Patient Follow-Up and Outcomes Assessment
-----------------------------------------

We assessed the outcomes of all patients through centralized telephone interviews by trained research coordinators (all were neurologists) at the participating hospitals. The outcomes of this study included stroke recurrence and all-cause death at 12 months. Stroke recurrence was defined as a new neurological deficit or re-hospitalization with a diagnosis of ischemic or hemorrhagic stroke ([@B12], [@B13]). Stroke recurrences associated with re-hospitalization were confirmed by the medical records from the attended hospitals. Case fatality was sourced to and confirmed on a death certificate from either the attended hospital or local citizen registry.

Statistical Analysis
--------------------

Categorical variables were presented as frequencies and percentages, while continuous variables were presented as mean with standard deviation or median with interquartile. The baseline characteristics of patients were compared among included and excluded patients, and among quartiles of glucose-to-HbA1c ratio using χ^2^ test for categorical variables (such as gender and medical histories) and ANOVA or the Kruskal-Wallis test for continuous variables (such as age and HbA1c).

The relationship of the categories of glucose-to-HbA1c ratio and the time to the first stroke recurrence and death were evaluated by proportional hazard Cox regression models with the lowest quartile as the reference. Through proportional hazard Cox regression models, we estimated adjusted hazard ratios (HRs) with their 95% confidence intervals (CIs) for each category of glucose-to-HbA1c ratio. We included a time-dependent covariate with interaction of the glucose-to-HbA1c ratio and a logarithmic function of survival time in the model to test the proportional hazard assumption. We performed three multivariate models to evaluate the association between glucose-to-HbA1c ratio and each outcome. In model 1, we only adjusted for age, gender, stroke severity, stroke subtype, and risk factors, including history of hypertension, history of hyperlipidemia, history of coronary heart disease and atrial fibrillation, and smoking status. In model 2, we additionally adjusted for complications during hospitalization, including pulmonary infection, and urinary infection. In model 3, we further adjusted for medicine use during hospitalization, including statins, thrombolytic, antiplatelet, antihypertensive, and anticoagulation agents.

Furthermore, we performed Cox regression models with restricted cubic splines for the glucose-to-HbA1c ratio (continuous variable) with adjustments for all potential covariates (model 3) to the pattern and magnitude of associations between the glucose-to-HbA1c ratio and the risk of stroke recurrence or death. The 25th percentile of the index of glucose-to-HbA1c ratio was used as the reference and the 5th, 25th, 50th, 75th, and 95th percentiles of the index of glucose-to-HbA1c ratio were used as the 5 knots for spline.

All analyses were performed by SAS software version 9.4 (SAS Institute Inc, Cary, NC). Two-sided *p* \< 0.05 was considered as statistically significant.

Results {#s3}
=======

Study Participants
------------------

The study enrolled a total of 1,623 consecutive non-diabetic patients with acute ischemic stroke. After excluding patients without a test of FPG or HbA1c, or those lost to follow-up at 12 months, a total of 999 (61.6%) patients were included in this analysis ([Figure 1](#F1){ref-type="fig"}). [Table 1](#T1){ref-type="table"} shows the baseline demography and disease characteristics of the patients included in and those excluded from this analysis. According to [Table 1](#T1){ref-type="table"}, the patients included and excluded were well-balanced except that those excluded for missing data of glucose had more stroke subtype of cardio embolism and those excluded for loss to follow-up had less stroke subtype of large artery atherosclerosis. The median age of the included 999 patients was 61.7 (range 19--92), among which 354 (35.6%) patients were female.

![Flow diagram of the patient selection.](fneur-10-01003-g0001){#F1}

###### 

Baseline characteristics of patients included and excluded.

  **Characteristics**                          **Included (*n* = 999)**   **Excluded for missing glucose or HbA1c (*n* = 371)**   **Excluded for loss to follow-up (*n* = 253)**   ***p***
  -------------------------------------------- -------------------------- ------------------------------------------------------- ------------------------------------------------ ---------
  Gender (female), *n* (%)                     354 (35.td)                111 (30.1)                                              81 (32.4)                                        0.14
  Age (year), mean (SD)                        61.7 ± 13.0                62.2 ± 13.8                                             62.3 ± 13.1                                      0.55
  History of hypertension, *n* (%)             586 (58.7)                 223 (60.1)                                              145 (57.3)                                       0.78
  History of hyperlipidemia, *n* (%)           106 (10.6)                 29 (7.8)                                                21 (8.3)                                         0.22
  History of atrial fibrillation, *n* (%)      61 (6.1)                   35 (9.4)                                                16 (6.3)                                         0.09
  History of coronary heart disease, *n* (%)   111 (11.1)                 49 (13.2)                                               21 (8.3)                                         0.16
  Smoking, *n* (%)                                                                                                                                                                 0.29
   Non-smoker                                  563 (56.4)                 224 (60.4)                                              143 (56.5)                                       
   Ever smoker                                 90 (9.0)                   41 (11.1)                                               25 (9.9)                                         
   Current smoker                              346 (34.6)                 106 (28.6)                                              85 (33.6)                                        
  NIHSS score on admission, median (IQR)       4 (2--8)                   4 (2--8)                                                4.5 (2--8.5)                                     0.79
  TOAST subtypes, *n* (%)                                                                                                                                                          0.001
   Cardio embolism                             63 (6.3)                   36 (9.7)                                                16 (6.3)                                         
   Large artery atherosclerosis                624 (62.5)                 238 (64.2)                                              147 (58.1)                                       
   Small artery occlusion                      256 (25.6)                 67 (18.1)                                               62 (24.5)                                        
   Other/undetermined                          22 (2.2)                   18 (4.9)                                                11 (4.3)                                         
   Undefined                                   34 (3.4)                   12 (3.2)                                                17 (6.7)                                         

*IQR, indicates interquartile range; NIHSS, National Institutes of Health stroke scale; SD, standard deviation; and TOAST, Trial of Org 10172 in Acute Stroke Treatment*.

Among the included patients, the median glucose-to-HbA1c ratio was 0.93 (interquartile: 0.83--1.07). The baseline demography and diseases characteristics of the patients by quartiles of glucose-to-HbA1c ratio were showed in [Table 2](#T2){ref-type="table"}. Patients with elevated level of glucose-to-HbA1c ratio were more likely to be non-smoker, have higher severity of stroke, higher proportion of pulmonary, and urinary infection. Additionally, patients with elevated level of glucose-to-HbA1c ratio had higher level of FPG (median FPG: 4.4, 5.0, 5.4, and 6.1 mmol/L in those with the 1st, 2nd, 3rd, and 4th quartile of glucose-to-HbA1c ratio) but lower level of HbA1c (median HbA1c: 5.9, 5.7, 5.5, and 5.0% in those with the 1st, 2nd, 3rd, and 4^th^ quartile of glucose-to-HbA1c ratio).

###### 

Baseline characteristics according to the stress hyperglycemia states measured by glucose-to-HbA1c ratio.

                                                 **Glucose-to-HbA1c ratio**   ***p* value**                                      
  ---------------------------------------------- ---------------------------- ---------------- ---------------- ---------------- ---------
  Gender (female), *n* (%)                       88 (34.5)                    89 (36.9)        77 (30.6)        100 (40.7)       0.12
  Age (year), mean (SD)                          61.7 ± 13.9                  63.1 ± 12.7      61.3 ± 12.6      60.6 ± 12.6      0.17
  Systolic blood pressure (mm Hg), mean (SD)     143.4 ± 19.1                 147.4 ± 22.9     147.2 ± 20.7     148.5 ± 21.2     0.06
  Diastolic blood pressure (mm Hg), mean (SD)    85.0 ± 11.4                  86.4 ± 12.5      86.3 ± 12.1      87.1 ± 12.4      0.49
  History of hypertension, *n* (%)               153 (59.5)                   138 (56.8)       153 (60.5)       142 (57.7)       0.83
  History of hyperlipidemia, *n* (%)             29 (11.3)                    27 (11.1)        27 (10.7)        23 (9.3)         0.90
  History of atrial fibrillation, *n* (%)        16 (6.2)                     12 (4.9)         15 (5.9)         18 (7.3)         0.75
  History of coronary heart disease, *n* (%)     26 (10.1)                    24 (9.9)         30 (11.9)        31 (12.6)        0.72
  Smoking, *n* (%)                                                                                                               0.01
   Non-smoker                                    132 (51.4)                   136 (56.0)       134 (53.0)       161 (65.4)       
   Previous smoker                               19 (7.4)                     27 (11.1)        26 (10.3)        18 (7.3)         
   Current smoker                                106 (41.2)                   80 (32.9)        93 (36.8)        67 (27.2)        
  Medicine use during hospitalization, *n* (%)                                                                                   
   Intravenous alteplase                         7 (2.7)                      9 (3.7)          11 (4.3)         6 (2.4)          0.61
   Antiplatelet                                  167 (65.0)                   157 (64.6)       158 (62.5)       156 (63.4)       0.93
   Anticoagulation                               9 (3.5)                      13 (5.3)         14 (5.5)         16 (6.5)         0.49
   Antihypertensive drugs                        110 (42.8)                   107 (44.0)       116 (45.8)       97 (39.4)        0.53
    Diuretics                                    5 (1.9)                      2 (0.8)          10 (4.0)         7 (2.8)          0.13
    Beta blockers                                9 (3.5)                      8 (3.3)          11 (4.3)         9 (3.7)          0.93
   Statin                                        144 (56.0)                   124 (51.0)       124 (49.0)       109 (44.3)       0.07
   Oral hypoglycemic agents                      12 (4.7)                     10 (4.1)         7 (2.8)          21 (8.5)         0.02
   Insulin                                       3 (1.2)                      2 (0.8)          3 (1.2)          13 (5.3)         0.001
  Pulmonary infection, *n* (%)                   14 (5.4)                     12 (4.9)         22 (8.7)         36 (14.6)        \<0.001
  Urinary infection, *n* (%)                     2 (0.8)                      7 (2.9)          15 (5.9)         16 (6.5)         0.003
  NIHSS score on admission, median (IQR)         4 (2--7)                     4 (2--7)         4 (2--8)         6 (3--11)        \<0.001
  TOAST subtypes, *n* (%)                                                                                                        0.92
   Cardio embolism                               16 (6.2)                     11 (4.5)         19 (7.5)         17 (6.9)         
   Large artery atherosclerosis                  164 (63.8)                   149 (61.3)       155(61.3)        156(63.4)        
   Small artery occlusion                        62 (24.1)                    72 (29.6)        65(25.7)         57(23.2)         
   Other/undetermined                            7 (2.7)                      4 (1.6)          5(2.0)           6(2.4)           
   Undefined                                     8 (3.1)                      7 (2.9)          9(3.6)           10(4.1)          
  FPG (mmol/L), median (IQR)                     4.4 (4.1--4.7)               5.0 (4.7--5.3)   5.4 (5.0--5.8)   6.1 (5.5--7.0)   \<0.001
  HbA1c (%), median (IQR)                        5.9 (5.6--6.2)               5.7 (5.4--6.0)   5.5 (5.1--5.9)   5.0 (4.5--5.6)   \<0.001
  Glucose-to-HbA1c ratio, median (IQR)           0.8 (0.7--0.8)               0.9 (0.9--0.9)   1.0 (1.0--1.0)   1.2 (1.1--1.3)   

*FPG, indicates fasting plasma glucose; HbA1c, glycated hemoglobin; IQR, interquartile range; NIHSS, National Institutes of Health stroke scale; SD, standard deviation; and TOAST, Trial of Org 10172 in Acute Stroke Treatment*.

*Quartiles of glucose-to-HbA1c ratio, Q1 = ≤ 0.82, Q2 = 0.83--0.92, Q3 = 0.93--1.06, Q4 = ≥1.07*.

Relationship Between Stress Hyperglycemia and Outcome
-----------------------------------------------------

There were 105 (10.9%) recurrent stroke and 76 (7.6%) death at 12 months. [Table 3](#T3){ref-type="table"} shows the 12-month outcomes after an ischemic stroke across quartiles of glucose-to-HbA1c ratio. Patients in the higher glucose-to-HbA1c ratio were associated with an elevated risk of stroke recurrence and death at 12 months (p for trend = 0.006 and 0.02, respectively). In the model with adjustment for patients demographics, stroke severity, stroke subtype, and vascular risk factors (model 1) and the model with further adjustment for complications (model 2), we found that patients with the highest quartile of glucose-to-HbA1c ratio was associated with an elevated risk of 12-month stroke recurrence and death. After further adjustment of medicine use during hospitalization (model 3), the highest quartile of glucose-to-HbA1c ratio remained to be associated with an elevated risk of 12-month stroke recurrence (16.0 vs. 8.3%; adj.HR = 2.19, 95%CI: 1.26--3.83) and death (13.0% vs. 4.3%; adj.HR=2.86, 95%CI: 1.38--5.90) compared with patients with the lowest quartile. All the assumptions of proportional hazards for Cox regression were met (*p* = 0.40 for the outcome of stroke recurrence and *p* = 0.10 for the outcome of death).

###### 

Adjusted hazard ratios of outcomes at 12 months according to glucose-to-HbA1c ratio quartiles.

  **Outcomes**        **Glucose-to-HbA1c groups**   ***n***   **Events, *n* (%)**   **Model 1[^\*^](#TN2){ref-type="table-fn"}**           **Model 2[^†^](#TN3){ref-type="table-fn"}**           **Model 3[^‡^](#TN4){ref-type="table-fn"}**   
  ------------------- ----------------------------- --------- --------------------- ---------------------------------------------- ------- --------------------------------------------- ------- --------------------------------------------- -------
  Stroke recurrence   Q1 (≤0.82)                    254       21 (8.3)              Ref.                                                   Ref.                                                  Ref.                                          
                      Q2 (0.83--0.92)               236       23 (9.7)              1.13 (0.62--2.04)                              0.69    1.14 (0.63--2.06)                             0.67    1.16 (0.64--2.10)                             0.64
                      Q3 (0.93--1.06)               346       24 (9.8)              1.22 (0.68--2.19)                              0.52    1.25 (0.69--2.25)                             0.46    1.26 (0.70--2.27)                             0.45
                      Q4 (≥1.07)                    231       37 (16.0)             2.09 (1.20--3.65)                              0.009   2.18 (1.25--3.80)                             0.006   2.19 (1.26--3.83)                             0.006
                      p for trend                                                                                                  0.009                                                 0.006                                                 0.006
  Death               Q1 (≤0.82)                    257       11 (4.3)              Ref.                                                   Ref.                                                  Ref.                                          
                      Q2 (0.83--0.92)               243       19 (7.8)              2.08 (0.98--4.40)                              0.06    2.06 (0.96--4.42)                             0.07    2.05 (0.96--4.38)                             0.07
                      Q3 (0.93--1.06)               253       14 (5.5)              1.36 (0.62--3.02)                              0.44    1.33 (0.60--2.96)                             0.49    1.31 (0.59--2.93)                             0.51
                      Q4 (≥1.07)                    246       32 (13.0)             2.68 (1.32--5.44)                              0.006   2.81 (1.36--5.79)                             0.005   2.86 (1.38--5.90)                             0.005
                      p for trend                                                                                                  0.02                                                  0.02                                                  0.02

*CI indicates confidence interval; HbA1c, glycated hemoglobin; and HR, hazard ratio*.

*Model 1: adjusted for age, gender, National Institutes of Health stroke score, stroke subtype, history of hypertension, hyperlipidemia, coronary heart disease, atrial fibrillation, and smoking status*.

*Model 2: adjusted for Model 1 + pulmonary infection and urinary infection during hospitalization*.

*Model 3: adjusted for Model 2 + statins, thrombolytic, antiplatelet, antihypertensive, and anticoagulation agents use during hospitalization*.

[Figure 2](#F2){ref-type="fig"} shows the non-linear relationship between level of glucose-to-HbA1c ratio and the risk of outcome events using Cox regression models with restricted cubic spline. We observed that higher level of glucose-to-HbA1c ratio was associated with an elevated risk of 12-month stroke recurrence and death.

![Adjusted hazard ratios of **(A)** stroke recurrence and **(B)** death according to glucose-to-HbA1c ratio. The solid line indicates adjusted hazard ratio and the dashed lines the 95% confidence interval bands. Reference is the 25th percentile of glucose-to-HbA1c ratio (0.83). The vertical dashed lines indicate the 1st, 2nd, and 3rd quartiles of glucose-to-HbA1c ratio. Data were fitted using a Cox regression model of restricted cubic spline with 5 knots (the 5th, 25th, 50th, 75th, 95th percentiles) for glucose-to-HbA1c ratio, adjusting for potential covariates. The lowest 5% and highest 5% of patients were not shown in the figures for small sample sizes.](fneur-10-01003-g0002){#F2}

Discussion {#s4}
==========

In this nationwide prospective registry study in China, we found that the stress hyperglycemia on admission measured by glucose-to-HbA1c ratio was associated with an elevated risk of stroke recurrence and mortality at 12 months in non-diabetic patients with acute ischemic stroke. Higher level of glucose-to-HbA1c ratio was associated with an elevated risk of poor prognosis of stroke.

There is a high prevalence of stress hyperglycemia in non-diabetic patients with acute illness like stroke, ranging from 8 to 63% based on variable study population and measurement of stress hyperglycemia ([@B3]). Several previous studies identified the stress hyperglycemia as a marker to predict higher risk of in-hospital mortality in patients with myocardial infarction ([@B14]), and higher risk of in-hospital mortality ([@B3]), 3-month poor functional outcome ([@B15]) and 3-month mortality ([@B16]) in non-diabetic patients with acute ischemic stroke. However, a Greece study showed that the association between stress hyperglycemia and in-hospital mortality after acute ischemic stroke did not persist after adjustment for stroke severity ([@B4]). Furthermore, these previous studies mostly measured stress hyperglycemia based on absolute increase of glycaemia with absence of diabetes. Our previous study showed that stress hyperglycemia, measured by the index of glucose-to-glycated albumin (GA) ratio, another relative measure of stress hyperglycemia, was associated with an elevated risk of 3-month new occurrence of stroke in patients with acute minor ischemic stroke or transient ischemic attack. The present study validated the association of stress hyperglycemia and long-term (12-month) stroke recurrence in a large-scale prospective stroke registry, and further added evidence that stress hyperglycemia was associated with higher risk of long-term (12 months) mortality in non-diabetic patients with acute ischemic stroke.

The mechanisms underlying the relationship between stress hyperglycemia and poor prognoses of stroke are not fully known. There were several explanations to understand the association. First, stress hyperglycemia may be a marker that represents the extent of ischemic damage after stroke. Stress hyperglycemia is relative rapid increase of blood glucose resulted from the neuro-hormonal derangements and inflammatory response that occur following the acute critical events like acute stroke ([@B1], [@B2]). Stress hyperglycemia is caused by high hepatic output of glucose resulting from a complicated interaction of hormones such as catecholamines, cortisol, and cytokines ([@B1]). Patients with severe or fatal strokes might develop stress hyperglycemia due to high level release of these inflammatory and vasoconstrictive factors ([@B3]). Second, hyperglycemia may be directly neurotoxic to the ischemic penumbra and caused more neurons to be injured and unviable ([@B17]--[@B19]). Third, oscillating glucose may aggravate injure of endothelial function and oxidative stress, which are two key factors that cause vascular events ([@B20], [@B21]). Fourth, hyperglycemic patients are relatively deficient in insulin ([@B3]). Our previous studies showed that insulin resistance and β-cell dysfunction were related to an elevated risk of poor outcome of non-diabetic patients with ischemic stroke ([@B12], [@B13]). Finally, hyperglycemia may have a deleterious effect on platelet function mediation by superoxide production and induce platelet aggregation ([@B22]). These pathological changes may result in a poor prognosis of stroke and tend to promote atherosclerosis and subsequent stroke. Our study also showed that the association between glucose-to-HbA1c ratio and outcome followed a threshold effect with an increased risk only in the highest quartile, indicating that sharp stress hyperglycemia may have more deleterious effect and result in a worse stroke outcome. The mechanism of underlining the association between stress hypoglycemia and poorer stroke outcome needs further investigation in the future. This also implicated that stress hyperglycemia was a potential treatment target to improve stroke outcome. However, this needs further investigation in well-designed randomized control trials.

In most of the previous studies, stress hyperglycemia was defined as absolute hyperglycemia without evidence of previously diagnosed diabetes or deterioration of pre-illness glycemic control with pre-existing diabetes ([@B1], [@B3]). But this diagnostic criterion did not consider the background glucose level and could not differentiate the stress hyperglycemia from diabetes. On the contrary, glucose-to-HbA1c ratio, the indicator we used to measure stress hyperglycemia, reflects a quantitative measurement of the relative acute rapid increase of blood glucose level based on glucose level prior stroke. Recent studies demonstrated that relative hyperglycemia, defined as glucose-to-HbA1c ratio ([@B6]) or defined as admission glucose level divided by estimated average blood glucose level obtained by regression with HbA1c ([@B2]), might be a better predicter for outcomes of critical diseases than absolute hyperglycemia. Furthermore, unlike glucose-to-GA ratio, another relative measure of stress hyperglycemia, measures based on HbA1c could be commonly used and generalized in the clinical practice. Glucose-to-HbA1c ratio could be more stable than glucose-to-GA ratio since HbA1c reflects mean glycaemia over \~2--3 months while GA only represents mean glycaemia over \~2--4 weeks. On the other hand, measures of stress hyperglycemia based on HbA1c required a separate specimen of whole blood and may be affected by chronic kidney disease, anemia, or hemoglobinopathies ([@B23]). Nevertheless, HbA1c is a well-established biomarker and is commonly used in the clinical practice. Our study has suggested an easy-to-perform approach to detect and quantify stress hyperglycemia. This could be of importance to predict the outcome of non-diabetic patients with ischemic stroke at the acute phage.

Several limitations should be acknowledged when explaining these results. First, about one third of patients were excluded due to failure to test fasting glucose or HbA1c, or loss to follow-up in this study. In fact, the baseline demography and disease characteristics were well-balanced among patients included in this analysis and those excluded, except that those included in the analysis had lower proportion of history of atrial fibrillation and stroke subtype of cardio embolism. Second, our study may have selection bias since only 35.6% of patients were female, median NIHSS scores are low (median score = 4), only 6.3% of patients had a cardio-embolic stroke and over 62.5% of patients had large-artery atherosclerosis. This may limit the generalization of our findings. Third, the generalizability of the results may be limited because only Chinese patients were enrolled in this study. The Chinese patients have a higher prevalence of intracranial atherosclerosis than the Western population ([@B24], [@B25]).

In conclusion, in this largescale stroke registry, stress hyperglycemia, measured by glucose-to-HbA1c ratio, was associated with an elevated risk of 12-month stroke recurrence and mortality in non-diabetic patients with acute ischemic stroke. Our findings may help doctors to assess the outcome of ischemic stroke at the acute phage in clinical practice.
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